Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

More than 100 federal scientists who track bird flu, including vaccine and food safety experts, have been laid off. This comes as the deadly pathogen rips through dairy herds and poultry flocks.

As spring temperatures rise along with pollen counts in Georgia, the state is seeing a decline in winter respiratory ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

This year's flu season has become the state's deadliest in nearly a decade, with at least 388 deaths so far. Meanwhile, flu ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...